Stockwinners Market Radar for April 02, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

11:54 EDT Nano-X Imaging announces 510(k) clearance for digital x-ray technology - Nano-X Imaging announced that its single-source Nanox.ARC digital x-ray technology has received 510(k) clearance from the Food and Drug Administration. The company said it remains on track and expects to submit a 510(k) application to the FDA for its multi-source Nanox.ARC and the Nanox.CLOUD in 2021. If cleared, the multi-source Nanox.ARC will be the company's commercial imaging system "that it expects to deploy broadly across the globe." Ran Poliakine, CEO of Nanox, said, "We remain on track to commence system shipments in the fourth quarter of 2021 and the first quarter of 2022 with the goal of finalizing deployment of the initial 15,000 Nanox.ARC systems by the end of 2024."

09:05 EDT Bank of America acquires health care payment company Axia - Bank of America announced that it has acquired Axia Technologies, a health care payment and technology company focused on facilitating secure patient payments. "The acquisition will deepen and expand Bank of America's payment offerings for healthcare clients and will further accelerate the bank's ability to serve this key vertical. It is part of a broader initiative to integrate merchant services onto its proprietary platform following the dissolution of its merchant services joint venture last year," Bank of America said in a statement. Terms of the acquisition were not disclosed.

08:47 EDT Tesla reports Q1 deliveries of 184,800, production of 180,338 - Tesla announced that in the first quarter, it produced just over 180,338 vehicles and delivered nearly 184,800 vehicles. "We are encouraged by the strong reception of the Model Y in China and are quickly progressing to full production capacity. The new Model S and Model X have also been exceptionally well received, with the new equipment installed and tested in Q1 and we are in the early stages of ramping production," Tesla said in a statement. Model S/X deliveries were 2,020 and Model 3/Y deliveries were 182,780. Tesla added, "Our net income and cash flow results will be announced along with the rest of our financial performance when we announce Q1 earnings. Our delivery count should be viewed as slightly conservative, as we only count a car as delivered if it is transferred to the customer and all paperwork is correct. Final numbers could vary by up to 0.5% or more."

08:24 EDT Redfin says median home sale price increased 17% year-over-year - The median home sale price increased 17% year-over-year to $335,613, an all-time high, according to a new report from Redfin. "However, year-over-year comparisons may more reflect the fact that this time last year, stay-at-home-orders halted both home-buying and selling activity. They don't necessarily reflect how the housing market has changed over the past year," the company said in a statement. Asking prices of newly listed homes rose 14% year-over-year to $353,500, an all-time high. Pending home sales were up 38% from the same period in 2020, and up 28% from the same period 2019, which was a more typical year for the housing market, Redfin said. Compared to the previous four-week period, pending sales grew 0.9%, the smallest growth between two Redfin housing market reports since the four-week period ending February 21, 2019. The company added that 59% of homes that went under contract had an accepted offer within the first two weeks on the market. "This is a new all-time high for this measure since at least 2012," according to Redfin.

08:19 EDT Apple adds over 30 titles to Arcade, bringing total to over 180 games - Apple announced that it is introducing two new game categories and adding more than 30 titles to Apple Arcade, its gaming subscription service. "In addition to new exclusive Arcade Originals, including "NBA 2K21 Arcade Edition," "Star Trek: Legends," and "The Oregon Trail," the service is introducing two new game categories, Timeless Classics and App Store Greats," Apple said in a statement. The two new categories bring the service's catalog to over 180 games. Apple Arcade is included as part of Apple One or for a monthly subscription of $4.99 with a one-month free trial.

08:15 EDT Emergent BioSolutions says 'disappointed' by COVID-HIG trial topline data - Emergent BioSolutions provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous, or "COVID-HIG," for the treatment of hospitalized patients with COVID-19. The Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin trial, also known as INSIGHT-013, sponsored and supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, assessed the safety and efficacy of four immunoglobulin candidates plus standard of care versus placebo plus standard of care in hospitalized patients with COVID-19. Topline data from the ITAC trial demonstrated that the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo. There were no serious safety concerns identified. COVID-HIG is also being developed as a potential treatment for outpatients at high risk of progression to severe disease with funding from BARDA. It is also being supported with funding from the U.S. Department of Defense. "While we are disappointed by these data in hospitalized patients where there remains a high unmet need, we recognize that, similar to other antibody-based therapies, intervention with COVID-HIG earlier in the disease course may be necessary to impact COVID-19 in patients. Emergent will continue to explore COVID-HIG as a treatment in ongoing clinical trials. The public-private partnership with NIAID and the Biomedical Advanced Research and Development Authority (BARDA) has been important to generate data on the COVID-HIG investigational product," said Dr. Laura Saward, SVP and therapeutics business unit head at Emergent BioSolutions.

08:08 EDT Churchill Capital VI says separate trading of stock, warrants to start April 5 - Churchill Capital Corp VI announced that commencing April 5, 2021, holders of the units sold in the company's initial public offering of 55.2M units may elect to separately trade the Class A common stock and warrants included in the units. Class A common stock and warrants that are separated will trade on the New York Stock Exchange under the symbols "CCVI" and "CCVI WS," respectively. Those units not separated will continue to trade on the New York Stock Exchange under the symbol "CCVI.U". No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

08:01 EDT Sinovac Biotech says annual capacity of CoronaVac has reached 2B doses - Sinovac Biotech announced that the third production line of CoronaVac, its COVID-19 vaccine, was completed and put into commercial production. Including this new production line, Sinovac's annual capacity of CoronaVac has reached 2 billion doses, the company stated. "At this time, over 200 million doses of CoronaVac have been delivered to over 20 countries, including China. It is estimated that over 100 million doses of CoronaVac have been administered during the vaccination rollout in different countries. The safety and effectiveness of CoronaVac has been proven gradually along with the rollout of the vaccination around the world. In the capacity expansion process, Sinovac adhered to the most stringent requirements and did not sacrifice quality for speed and expansion. The new production line has been inspected by China's National Medical Products Administration in compliance with quality specifications. Thus far, Sinovac's COVID-19 vaccine received emergency use approval, or conditional marketing authorization, by over 30 countries. The facility and quality management system of CoronaVac has been inspected by China, Brazil, Indonesia, Chile, Singapore, and Saudi Arabia, as well as the World Health Organization. The large-scale production of hundreds of batches of COVID-19 vaccine proved that the vaccine production process is controllable and the quality is reliable," the company said.